Biognosys Conference Resources - Biognosys

Biognosys Conference Resources

Biognosys Portfolio – Transformative Insights from Discovery to Clinic

This comprehensive brochure provides an overview of our services, software, and kits offering.

TrueDiscovery™ Brochure – Unbiased Biological Insights from Tissue and Biofluids

The brochure provides you with an overview of the key features and benefits of our next-generation TrueDiscovery™ platform. In addition, it elaborates on our deep and reproducible proteome, phospho- and immune-proteome quantification and analysis. Finally, it digs into how we identify the most promising and actionable biomarkers for research and clinical decision-making.

TrueTarget™ Brochure – Novel Drug Target Identification and Validation

Learn more about Biognosys’ proprietary TrueTarget™ platform in our latest brochure. This resource elaborates on how TrueTarget™ identifies the most promising and actionable drug targets to support your research.

TrueSignature™ Brochure – Custom Panels for Absolute Protein Quantification

The brochure provides you with an overview of the key features and benefits of our next-generation TrueSignature™ platform. In addition, it elaborates on the specificities of our customizable panels for clinical and pharmacodynamics studies.

Case Study – Biomarker Candidates for Tumors Identified from Deep‐profiled Plasma Stem Predominantly from the Low Abundant Area

The case study provides you with an overview of the key features and benefits of our next-generation Plasma Biomarker Discovery solution. In addition, the case study elaborates on the results from our latest pan-cancer proteomics study.

Case Study – Biognosys Immunopeptidome Profiling Solution for MHC Class I And Class II Neoantigens Discovery in Tumor Biopsies

The case study provides you with an overview of the key features and benefits of our next-generation Immunopeptidome Profiling solution. In addition, the case study elaborates on the results of our latest immunopeptidomics study on lung cancer.

Case Study – Multi-omics Biomarker Analysis Identifies Unique Immune Activation Signature in Pancreatic Cancer

We describe a first-of-its-kind study using multi-omics biomarker approaches to demonstrate pharmacodynamic effects and immune modulation in pancreatic cancer. Biognosys’ proprietary platform for unbiased proteomics, TrueDiscovery™, allowed the identification of pharmacodynamic markers and elucidated the mechanism of action of therapies under clinical investigation.

White Paper – A Comparative Study of Mass Spectrometry and Affinity-based Platforms

Harnessing the information present in the plasma proteome requires robust large-scale analytical techniques. Our latest white paper gives you a better understanding of two leading technology platforms for Plasma Proteomics: Biognosys’ TrueDiscovery™ and Olink Explore.

White Paper – Accelerating Biomarker Discovery With Large-Scale Plasma Proteomics

In this white paper, we explain how advances in mass spectrometry can now unlock the potential of the plasma proteome, uncovering actionable insights essential for biomarker discovery and targeted drug development.

White Paper – How To Accelerate And De-Risk Drug Development In Oncology

In this white paper, you can learn about the key reasons why oncology drug development fails and how Biognosys’ proteomics platforms and applications can support your oncology research pipeline.

Contact

    Close banner

    New: Hyperplex Biomarker Panels

    Custom Panels for Absolute Protein Quantification

    New: Hyperplex Biomarker Panels

    Custom Panels for Absolute Protein Quantification

    Learn More